Online inquiry

IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13883MR)

This product GTTS-WQ13883MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRB gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002609.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5159
UniProt ID P09619
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13883MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6089MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ4804MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ13664MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ9628MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ11652MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ13625MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ12433MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ12386MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NEOD-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW